A novel oral partial adenosine A1 receptor agonist for the treatment of heart failure: safety and tolerability in healthy volunteers pretreated with beta-blocker
Boehringer Ingelheim, Ingelheim am Rhein (Germany)
0
follower
9
more
presentations
in this session
Efficacy of trimetazidine on functional capacity in symptomatic patients with moderately reduced or left ventricular dysfunction and CAD: a subgroup analysis of the VASCO trial